• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    5/18/23 1:31:34 PM ET
    $ALIM
    $AVRO
    $AVTX
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALIM alert in real time by email

    Gainers

    • Enveric Biosciences (NASDAQ:ENVB) stock rose 113.8% to $3.25 during Thursday's regular session. The current volume of 89.5 million shares is 277186.5% of Enveric Biosciences's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $6.7 million. The company's, Q1 earnings came out 3 days ago.
    • Alimera Sciences (NASDAQ:ALIM) stock rose 45.63% to $3.0. As of 13:30 EST, this security is trading at a volume of 29.2 million shares, making up 122706.4% of its average full-day volume over the last 100 days. The company's market cap stands at $22.1 million. As per the news, the Q1 earnings report came out 3 days ago.
    • Phio Pharma (NASDAQ:PHIO) stock rose 36.7% to $5.14. As of 13:30 EST, this security is trading at a volume of 12.2 million shares, making up 4601.8% of its average full-day volume over the last 100 days. The company's market cap stands at $7.7 million.
    • Avrobio (NASDAQ:AVRO) stock moved upwards by 28.68% to $0.74. Trading volume for Avrobio's stock is 8.6 million as of 13:30 EST. This is 1966.1% of its average full-day volume over the last 100 days. The company's market cap stands at $32.7 million.
    • Cue Health (NASDAQ:HLTH) stock moved upwards by 26.89% to $0.8. Cue Health's stock is trading at a volume of 2.0 million shares as of 13:30 EST. This is 590.5% of its average full-day volume over the last 100 days. The company's market cap stands at $121.1 million.
    • Avalo Therapeutics (NASDAQ:AVTX) stock increased by 19.89% to $3.35. As of 13:30 EST, Avalo Therapeutics's stock is trading at a volume of 620.4K, which is 2163.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $44.1 million.

    Losers

    • NanoString Technologies (NASDAQ:NSTG) shares fell 26.4% to $6.26 during Thursday's regular session. As of 13:30 EST, NanoString Technologies's stock is trading at a volume of 4.3 million, which is 672.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $296.3 million.
    • Fortress Biotech (NASDAQ:FBIO) stock fell 23.14% to $0.52. The current volume of 4.0 million shares is 718.3% of Fortress Biotech's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $67.9 million.
    • Motus GI Hldgs (NASDAQ:MOTS) stock fell 19.92% to $0.8. Trading volume for Motus GI Hldgs's stock is 701.8K as of 13:30 EST. This is 239.7% of its average full-day volume over the last 100 days. The company's market cap stands at $3.8 million.
    • Mallinckrodt (AMEX:MNK) shares declined by 15.63% to $1.35. As of 13:30 EST, this security is trading at a volume of 79.9K shares, making up 191.5% of its average full-day volume over the last 100 days. The company's market cap stands at $17.7 million.
    • AgeX Therapeutics (AMEX:AGE) shares declined by 14.06% to $0.45. Trading volume for AgeX Therapeutics's stock is 116.0K as of 13:30 EST. This is 720.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $17.2 million. As per the news, the Q1 earnings report came out 4 days ago.
    • ImmunityBio (NASDAQ:IBRX) shares fell 13.37% to $2.8. Trading volume for this security as of 13:30 EST is 4.2 million, which is 70.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.2 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALIM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALIM
    $AVRO
    $AVTX
    $ENVB

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    Avalo Therapeutics Inc.
    $AVTX
    9/17/2025$15.00 → $25.00Buy
    H.C. Wainwright
    Avalo Therapeutics Inc.
    $AVTX
    9/5/2025Buy
    TD Cowen
    Avalo Therapeutics Inc.
    $AVTX
    8/15/2025Overweight
    Cantor Fitzgerald
    Phio Pharmaceuticals Corp.
    $PHIO
    6/5/2025$14.00Buy
    H.C. Wainwright
    Avalo Therapeutics Inc.
    $AVTX
    6/2/2025$15.00Buy
    H.C. Wainwright
    ImmunityBio Inc.
    $IBRX
    5/20/2025$5.00Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $ALIM
    $AVRO
    $AVTX
    $ENVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science

    3/10/26 10:21:44 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT

    The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com KING OF PRUSSIA, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 12th, 2026. Mr. Bitterman

    3/10/26 7:59:39 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT

    The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.comKing of Prussia, Pennsylvania--(Newsfile Corp. - March 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 12th, 2026. Mr. Bit

    3/10/26 7:00:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALIM
    $AVRO
    $AVTX
    $ENVB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ALIM
    $AVRO
    $AVTX
    $ENVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Avalo Therapeutics with a new price target

    Mizuho initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $39.00

    12/18/25 9:07:24 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright reiterated coverage on Avalo Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $25.00 from $15.00 previously

    9/17/25 11:38:46 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALIM
    $AVRO
    $AVTX
    $ENVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Pres. & CEO Bitterman Robert J bought $5,150 worth of shares (5,000 units at $1.03), increasing direct ownership by 2% to 291,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    1/2/26 4:05:06 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,100 worth of shares (5,000 units at $1.02), increasing direct ownership by 2% to 286,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    12/29/25 8:10:21 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,700 worth of shares (5,000 units at $1.14), increasing direct ownership by 2% to 281,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    11/24/25 12:54:10 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALIM
    $AVRO
    $AVTX
    $ENVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Legal Officer Varki Paul

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    3/2/26 4:24:17 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Strategy Officer Riley Jennifer

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    3/2/26 4:23:32 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Doyle Mittie

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    3/2/26 4:23:06 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALIM
    $AVRO
    $AVTX
    $ENVB
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Avalo Therapeutics Inc.

    SCHEDULE 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    3/6/26 10:05:20 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Phio Pharmaceuticals Corp.

    10-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)

    3/5/26 4:17:45 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)

    3/5/26 4:10:23 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALIM
    $AVRO
    $AVTX
    $ENVB
    Leadership Updates

    Live Leadership Updates

    View All

    Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

    Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ.Robert Bitterman, CEO and Chairman of the Board of Phio Pharmaceuticals will deliver a company presentation on January 28th at 9 AM in Borgata Hotel Room #1 and the management team will be avai

    1/26/26 8:15:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman

    ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as Chairman of the Board. Mr. Johnson will work alongside CEO, Doron Besser, and the existing leadership team. David Johnson, newly appointed Chairman of ENvue, stated, "We believe ENvue is at the forefront of advanced feeding-tube placement technology, which has been validated in the market and extensively used in the clinic across 38 hospitals in the US. In my opinion, the Company's unique feeding tube placement system that utilizes advanced methods of navigation, integrated sensors and body mapping h

    12/15/25 9:00:00 AM ET
    $ENVB
    $FEED
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    $ALIM
    $AVRO
    $AVTX
    $ENVB
    Financials

    Live finance-specific insights

    View All

    ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

    ImmunityBio, Inc. ((IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company's clinical trial pipeline, and to review financial results for the year ended December 31, 2025. Conference Call Details The conference call will begin at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Tuesday, March 3, 2026. Interested parties may access the conference call through our Investor Relations website, ir.immunitybio.com, under Company — Events & Presentations. Alternatively, individuals can access the call by dialing 1-844-539-3703 or 1-412-652-1273 (internationally).

    2/27/26 7:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

    MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for gross proceeds of $205 million upon the closing of the transaction. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl") assumed full responsibility for the development and commercialization of ZYCUBO® (copper histidinate, formerly known as CUTX-101) from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration ("FDA") on January 12, 2026

    2/23/26 9:24:14 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

    MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for gross proceeds of $205 million upon the closing of the transaction. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl") assumed full responsibility for the development and commercialization of ZYCUBO® (copper histidinate, formerly known as CUTX-101) from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration ("FDA") on January 12, 2026

    2/23/26 8:30:00 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALIM
    $AVRO
    $AVTX
    $ENVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avalo Therapeutics Inc.

    SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/14/24 6:23:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Motus GI Holdings Inc.

    SC 13G/A - Motus GI Holdings, Inc. (0001686850) (Subject)

    11/14/24 4:22:34 PM ET
    $MOTS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Enveric Biosciences Inc.

    SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)

    11/14/24 4:03:47 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care